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Abstract
Purpose Use of automated perfusion software has gained importance for imaging of stroke patients for mechanical
thrombectomy (MT). We aim to compare four perfusion software packages: 1) with respect to their association with
3-month functional outcome after successful reperfusion with MT in comparison to visual Cerebral Blood Volume -
Alberta Stroke Program Early CT Score (CBV-ASPECTS) and collateral scoring and 2) with respect to their agreement
in estimation of core and penumbra volume.
Methods This retrospective, multicenter cohort study (2015–2019) analyzed data from 8 centers. We included patients
who were functionally independent before and underwent successful MT of the middle cerebral artery. Primary outcome
measurements were the relationship of core and penumbra volume calculated by each software, qualitative assessment of
collaterals and CBV-APECTS with 3-month functional outcome and disability (modified Rankin scale >2). Quantitative
differences between perfusion software measurements were also assessed.
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Results A total of 215 patients (57% women, median age 77 years) from 8 centers fulfilled the inclusion criteria. Multivari-
able analyses showed a significant association of RAPID core (common odds ratio, cOR 1.02; p= 0.015), CBV-ASPECTS
(cOR 0.78; p= 0.007) and collaterals (cOR 0.78; p= 0.001) with 3-month functional outcome (shift analysis), while RAPID
core (OR 1.02; p= 0.018), CBV-ASPECTS (OR 0.77; p= 0.024), collaterals (OR 0.78; p= 0.007) and OLEA core (OR 1.02;
p= 0.029) were significantly associated with 3-month functional disability. Mean differences on core estimates between
VEOcore and RAPID were 13.4ml, between syngo.via and RAPID 30.0ml and between OLEA and RAPID –3.2ml.
Conclusion Collateral scoring, CBV-ASPECTS and RAPID were independently associated with functional outcome at 90
days. Core and Penumbra estimates using automated software packages varied significantly and should therefore be used
with caution.
Keywords Acute ischemic stroke · Perfusion imaging · Collaterals · Automated evaluation · Patient selection
Introduction
Software packages that automatically postprocess com-
puted tomographic perfusion (CTP) images and provide
CTP-based core and penumbra estimates have been used in
various randomized controlled mechanical thrombectomy
(MT) trials for acute ischemic stroke patients due to a large
vessel occlusion (LVO) [1, 2]. The underlying concept is
that of an ischemic core of irreversibly damaged tissue,
surrounded by an area of oligemic tissue, the penumbra
[3, 4]. In theory, immediate reperfusion of the penumbra
would save the affected tissue at risk, and a large infarct
core or/and a small core-penumbra mismatch would indi-
cate that there is little or no tissue that can be saved. Thus,
the general approach in many comprehensive stroke centers
is to decide in favor of MT when there is a small infarct
core and a large mismatch, and to refrain from it when
a large core and only a small or no mismatch is present on
CTP maps [5].
While current guidelines suggest that perfusion imaging
is not required within the first 6h after symptom onset [6,
7], perfusion is a relevant tool for the selection of patients
within 6–24h of last time known well, because the two
late window MT trials, DAWN and DEFUSE 3 [8, 9] re-
lied on perfusion-derived core and penumbra estimates for
patient selection, and this has translated into guideline rec-
ommendations [7–9]. Both DAWN and DEFUSE 3 used the
RAPIDTM software (https://ischemaview.com/home) to gen-
erate perfusion-based core and penumbra volumes; how-
ever, various other perfusion packages from different ven-
dors have been introduced and refined the last years, none
of which were tested and validated in randomized trials.
While ischemic core is defined on relative cerebral blood
flow in most software, parameters to assess the penumbra
vary across vendors and software packages [1, 3, 10]. Col-
lateral flow status is a visually assessed biomarker that has
been used in past MT trials [11] and a secondary analysis
of the MR CLEAN trial supported the association of collat-
erals and treatment effect in stroke patients with LVO [6].
Due to the additional cost and time requirements related
to automated perfusion analysis, physicians often visually
assess perfusion imaging by applying the Alberta Stroke
Program Early CT Score (ASPECTS) to the color-coded
perfusion maps as a decision support tool in LVO patients
[12] rather than relying on postprocessed threshold maps.
In this multicenter study, we therefore aimed to deter-
mine the value of four different commercially available
automated perfusion software packages for estimation of
infarct core and penumbral mismatch in patients presenting
with LVO. Additionally, we evaluated the association of
core and penumbral volumes derived from these perfusion
software packages, an established collateral score and the
cerebral blood volume (CBV-)ASPECTS with functional
outcome 90 days after MT and with the extent of cerebral
infarction 24h following stroke symptom onset.
Material andMethods
The data that support the findings of this study are available
from the corresponding author on reasonable request.
Study Design
Large vessel occlusion patients from 8 high-volume stroke
centers across Europe, USA and Canada between January
2015 and June 2019 were retrospectively analyzed. The pa-
tients were derived from registries kept by the respective
centers. All registries were approved by the respective lo-
cal ethics committee. All data were anonymized prior to ex-
traction. Inclusion criteria were a) functional independence
prior to the index event (modified Rankin scale, mRS ≤2),
b) successful reperfusion defined as modified thrombolysis
in cerebral infarction (mTICI) score of 2b or better, c) time
from perfusion scan to successful reperfusion <180min and
d) occlusion of the M1 or M2 segment of the middle cere-
bral artery (MCA). Exclusion criteria were a) missing pre-
stroke mRS or 90 days mRS, and b) failure to calculate
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the ischemic core/mismatch volume or collaterals/CBV-
ASPECTS due to technical reasons.
Study Population
A total of 215 patients (122, 57% women) from 8 cen-
ters were evaluated. Out of the 215 patients, 33 (15%) pa-
tients were excluded from the final analysis due to tech-
nical failure of at least 1 perfusion software. Median age
was 77 years (interquartile range, IQR 67–83 years), and
63 patients (29%) presented with a wake-up stroke. Me-
dian National Institute of Health Stroke Scale (NIHSS) at
presentation was 14 (IQR 8–18) and the perfusion datasets
were acquired on median 88 min (IQR 66–145 min) after
symptom onset. A summary of the baseline characteristics
is shown in Table 1.
Table 1 Baseline characteristics of the patient cohort
Variable N= 182
Age (median) (IQR) (years) 77 (68–83)
Female sex (n) (%) 104 (57%)
Wake-up stroke (n) (%) 56 (31%)
Baseline NIHSS score (median) (IQR) 13 (8–18)
Hypertension (n) (%) 144 (79%)
Diabetes (n) (%) 47 (26%)
Hyperlipidemia (n) (%) 82 (45%)
Smoking (n) (%) 29 (16%)
Obesity (n) (%) 40 (22%)
Time from onset to imaging (median) (IQR)
(min)
90 (68–185)
Time from imaging to reperfusion (median)
(IQR) (min)
83 (60–101)
Time from onset to reperfusion (median) (IQR)
(min)
198 (145–270)
Left side occlusion (n) (%) 93 (51%)
Occluded segment of MCA (n) (%)
M1 138 (76%)
M2 44 (24%)
Intravenous thrombolysis (n) (%) 104 (57%)
Tandem occlusion (n) (%) 18 (10%)
mTICI score post thrombectomy (n) (%)
mTICI 2b 62 (34%)
mTICI 2c 29 (16%)
mTICI 3 91 (50%)
Number of passes (median) (IQR) 1 (1–2)
ASPECTS 24h after stroke (median) (IQR) 8 (6–9)
90-day mRS (median) (IQR) 3 (1–5)
90-day functional independence (mRS <3)
(No.) (%)
89 (49%)
90-day mortality (n) (%) 44 (24%)
ASPECTS Alberta Stroke Program Early Computed Tomography
Score, IQR interquartile range, MCA middle cerebral artery,
mRS modified Rankin scale, mTICI modified treatment in cerebral
ischemia, NIHSS National Institutes of Health Stroke Scale
OutcomeMeasures
Primary outcomes were the association of the core and
penumbral estimates derived from the four perfusion soft-
ware, collaterals and CBV-ASPECTS with 3-month func-
tional outcome (mRS score shift analysis) and with 3-month
functional disability (mRS score >2). Secondary outcomes
included the mean differences of the ischemic core and
penumbral volumes derived from three other perfusion soft-
ware packages compared to the established RAPID soft-
ware.
Demographic data, vascular risk factors, mTICI scores,
time from symptom onset to imaging, imaging to reperfu-
sion, groin to reperfusion and neurological scores were ex-
tracted from the databases. Image analysis was performed
by an experienced neuroradiologist blinded to patient’s
functional outcome at 3 months, whereas neurological
status was assessed by stroke neurologists at hospital ad-
mission, hospital discharge, and on follow-up. Successful
recanalization was defined as mTICI 2b, 2c or 3. Perfusion
imaging was acquired on the following scanners: Somatom
Definition AS+ (Siemens Healthcare Sector, Forchheim,
Germany), Philips Brilliance 6 (Philips Healthcare, Best,
The Netherlands), Philips Brilliance 64 (Philips Health-
care), Philips iCT 256 (Philips Healthcare), Somatom
Definition AS (Siemens Healthcare Sector), Somatom Def-
inition Flash (Siemens Healthcare Sector), Revolution CT
(GE Healthcare, Chalfont St Giles, UK) and Discovery
CT (GE Healthcare) using standard perfusion protocols
[13]. The study was approved by the ethics committee
of the University Hospital Basel, Basel, Switzerland, in
accordance with the Declaration of Helsinki, with waiver
of informed consent. Data were deidentified as previously
described.
Software Packages and Image Analysis
Four different software packages were used for the esti-
mation of core and penumbra volume: RAPID v4.9.1.2
(iSchemaView Inc, Menlo Parc, CA, USA); VEOcore v1.1
(VEObrain GmbH, Freiburg, Germany); OLEA v3.0-SP18
(OLEA medical Inc., La Ciotat, France) and syngo.via
VB30A_HF06 (Siemens Healthineers AG, Erlangen, Ger-
many). We used the vendor prespecified standard settings
and thresholds in all software packages. Postprocessing
was centralized and standardized for all datasets after the
different centers sent the raw data of the perfusion software
to the core laboratory. The CBV maps were calculated
with syngo.via using the built-in CT Neuroperfusion work-
flow. The color maps were not manually adapted. One
experienced (>10-year experience after board certifica-
tion) neuroradiologist evaluated the CBV maps using the
ASPECTS according to the current methodology and ad-
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ditionally scored the maximum intensity projections of the
CT angiography (CTA) using the 10-point Menon collateral
score [14]. The CBV-ASPECTS and collateral scores were
assessed independently and blinded to all clinical data.
Statistical Analysis
First, we calculated the median with corresponding IQR of
the provided core and penumbra volumes for every soft-
ware packages. We used the non-parametric Friedman’s
test to assess for potential differences in estimated core
and penumbra volumes across the different software pack-
ages. The Conover test was then used for post hoc pair-
wise comparisons between these different software pack-
ages. Correlations between these various platform specific
core/penumbra volumes were also tested using the nonpara-
metric Spearman’s test.
We then calculated the mean pairwise differences and
corresponding 95% confidence intervals (CI) for penumbra
and core volume estimates as provided by different software
packages and assessed the degree of agreement graphically
with the use of Bland-Altman plots. We additionally eval-
uated in multivariable regression models the association of
noncontrast CT (NCCT-)ASPECTS at 24h, 3-month func-
tional outcome assessed with the mRS score, and 3-month
functional disability (mRS >2) with the CBV-ASPECTS,
collateral score, and core and penumbra volumes provided
by different software packages. All baseline characteristics
that contributed to the corresponding outcome of interest in
the initial univariable ordinal and binary logistic regression
analyses at p-values <0.1 were included in the multivari-
able models as candidate variables. The final variables that
were independently associated in the multivariable binary
or ordinal logistic regression analyses with the outcomes of
interest were selected using a two-sided alpha value <0.05.
Finally, we performed separate receiver operating char-
acteristic (ROC) curve analyses on the prognostic utility of
CBV-ASPECTS, collateral score and core volumes pro-
vided by different software packages for 3-month func-
tional disability. The individual areas under the ROC curves
(AUC) were compared with the DeLong’s test.
All statistical analyses were conducted with the Stata
Statistical Software Release 13 (StataCorp LP, College Sta-
tion, TX, USA).
Results
Univariable and Multivariable Analyses of Clinical
and Imaging Outcomes
Results of the univariable logistic regression analyses on
the association of baseline characteristics with the 3-month
Table 2 Multivariable ordinal regression on the association of
CBV-ASPECTS, collateral score and estimated core volume





CBV-ASPECTS 0.78 (0.65, 0.93) 0.007
Collateral score 0.78 (0.68, 0.91) 0.001
RAPID Core volume (ml) 1.02 (1.01, 1.03) 0.015
RAPID Penumbra volume (ml) 1.00 (0.99, 1.01) 0.899
VEOcore Core volume (ml) 1.00 (0.99, 1.01) 0.456
VEOcore Penumbra volume
(ml)
1.00 (0.99, 1.01) 0.586
syngo.via Core volume (ml) 1.00 (0.99, 1.01) 0.941
syngo.via Penumbra volume
(ml)
1.01 (1.00, 1.02) 0.209
OLEA Core volume (ml) 1.01 (1.00, 1.03) 0.076
OLEA Penumbra volume (ml) 1.00 (1.00, 1.01) 0.369
All associations were adjusted for the variables: age, wake-up stroke,
prestroke modified Rankin Scale (mRS), baseline National Institute
of Health Stroke Scale (NIHSS), hypertension, diabetes, time from
symptom onset to imaging, time from symptom onset to reperfusion,
final modified Thrombolysis In Cerebral Infarction (mTICI),
intravenous thrombolysis pretreatment; CBV-ASPECTS Cerebral
Blood Volume Alberta Stroke Program Early CT Score, p Statistical
significant
Table 3 Multivariable logistic regression analyses on the association
of CBV-ASPECTS, collateral status and software core and penumbral
parameters with 3-month functional disability (mRS >2), adjusted for
baseline characteristics
Variable OR (95%CI) p-value
CBV-ASPECTS 0.77 (0.62, 0.96) 0.024
Collateral score 0.78 (0.66, 0.94) 0.007
RAPID Core volume (ml) 1.02 (1.01, 1.04) 0.018
RAPID Penumbra volume (ml) 1.00 (0.99, 1.01) 0.412
VEOcore Core volume (ml) 1.00 (0.99, 1.00) 0.265
VEOcore Penumbra volume
(ml)
1.00 (0.99, 1.01) 0.228
syngo.via Core volume (ml) 1.00 (0.99, 1.01) 0.283
syngo.via Penumbra volume
(ml)
1.01 (1.00, 1.02) 0.080
OLEA Core volume (ml) 1.02 (1.00, 1.05) 0.029
OLEA Penumbra volume (ml) 1.00 (0.99, 1.01) 0.192
All associations were adjusted for the variables: age, pre-stroke
modified Rankin Scale (mRS), baseline National Institute of Health
Stroke Scale (NIHSS), hypertension, time from symptom onset to
imaging, intravenous thrombolysis, final modified Thrombolysis In
Cerebral Infarction (mTICI); CBV-ASPECTS Cerebral Blood Volume
Alberta Stroke Program Early CT Score, p Statistical significant
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Table 4 Prediction of disability (mRS >2) at 3 months with CBV-ASPECTS, collateral score and software core estimation
Variable Area under the Curve Standard Error Asymptomatic Normal (95% Conf. Interval)
CBV-ASPECTS 0.6960 0.0385 0.6206–0.7715
Collateral score 0.7015 0.0388 0.6254–0.7776
RAPID Core volume (ml) 0.6672 0.0397 0.5894–0.7449
VEOcore Core volume (ml) 0.6181 0.0425 0.5348–0.7014
syngo.via Core volume (ml) 0.6356 0.0417 0.5539–0.7174
OLEA Core volume (ml) 0.6531 0.0411 0.5726–0.7337
Results are derived from ROC analysis; CBV-ASPECTS Cerebral Blood Volume Alberta Stroke Program Early CT Score
Table 5 Mean pairwise differences (in ml) with corresponding 95% confidence intervals in brackets between the core volume estimates of the
four software packages
RAPID VEOcore syngo.via OLEA
RAPID – 13.4 (–9.8 to 36.6) 30.0 (23.7 to 36.4) –3.2 (–6.1 to –0.2)
VEOcore –13.4 (–36.6 to 9.8) – 16.6 (–7.5 to 40.7) –16.6 (–40.0 to 6.8)
Syngo.Via –30.0 (–36.4 to –23.7) –16.6 (–40.7 to 7.5) – –33.2 (–40.2 to –26.2)
OLEA 3.2 (0.2 to 6.1) 16.6 (–6.8 to 40.0) 33.2 (26.2 to 40.2) –
Analysis performed with Bland-Altman plots
mRS, with the 3-month functional disability (mRS >2)
and with the 24h NCCT-ASPECTS can be found in eTa-
bles 1–3 of the online only supplements. Multivariable anal-
yses showed a significant association of RAPID core mea-
surements (common odds ratio, cOR per ml 1.02; 95% CI
1.01–1.03), CBV-ASPECTS (cOR per point 0.78; 95% CI
0.65–0.93) and collaterals (cOR per point 0.78; 95% CI
0.68–0.91) with the 3-month functional outcome (Table 2).
Similar findings were identified for the association of imag-
ing parameters with the 3-month functional disability as
RAPID core (OR per ml 1.02; 95% CI 1.01–1.04), CBV-
ASPECTS (OR per point 0.77; 95% CI 0.62–0.96), collater-
als (OR per point 0.78; 95% CI 0.66–0.94) and OLEA core
(OR per ml 1.02; 95%CI 1.00–1.05) emerged as indepen-
Fig. 1 Receiver operating characteristic analyses for the prediction of
disability (mRS >2) at 3 months for CBV-ASPECTS, collateral status
and software core estimates
dent predictors of 3-month functional disability (Table 3).
Regarding the association of baseline imaging parameters
with the 24h NCCT-ASPECTS, RAPID core, VEOcore
core and OLEA core were all independently associated with
the extent of infarction on follow-up imaging, while CBV-
ASPECTS and collaterals showed the strongest association
(eTable 4). The efigures 1–3 of the online-only supplements
depict Bland-Altmann plots on the agreement of the vari-
ous core measurements with core volumes measured with
RAPID. Regarding the prediction of functional disability at
day 90 poststroke, all imaging parameters had similar area
under the curve values (p-value for DeLong’s test= 0.145;
Table 4 and Fig. 1).
Core and Penumbra Estimations with Different
Perfusion Software
The comparison of core and penumbra estimations between
the four software packages resulted in significant differ-
ences as shown in eTable 5. The mean difference with cor-
responding 95% CI on ischemic core estimates between
VEOcore and RAPID was 13.4ml (95% CI –9.8, 36.6), be-
tween syngo.via and RAPID 30ml (95% CI 23.7, 36.4) and
between OLEA and RAPID –3.2ml (95% CI –6.1, –0.2)
(Table 5). Positive mean differences indicated a larger mean
core volume compared to RAPID, while negative mean dif-
ferences indicated a smaller mean core volume compared to
RAPID. Mean differences between software on penumbra
volume estimates can be found in eTable 6. Spearman corre-
lation coefficients between the different perfusion software
regarding ischemic core and penumbra imaging estimation
showed high variance and can be found in eTables 7 and 8.
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Discussion
Our analysis indicates that visual assessment of a single-
phase CTA collateral score or of CBV-ASPECTS are at
least similar to automated perfusion evaluation in predict-
ing functional outcome at 90 days poststroke. The model us-
ing single-phase CTA collaterals had the highest predictive
power for functional disability at 90 days. Collaterals and
CBV-ASPECTS were both independently associated with
functional outcome and functional disability at 90 days.
From the four software packages only the core estimate of
RAPID was independently associated with functional out-
come at 90 days.
After the publication of the DAWN and DEFUSE-3 tri-
als, automated estimations of ischemic core and penum-
bra volumes by RAPID became part of the guidelines for
the selection of stroke patients eligible for MT in the late
time window [7]; however, due to the costs of software
packages, many hospitals prefer easily applicable selec-
tion tools, such as CBV-ASPECTS and collateral scoring
in clinical routine. While CBV-ASPECTS has only been
evaluated in smaller, retrospective cohorts [12] collateral
scoring has already been validated in a large randomized
controlled clinical trial for the time window of up to 12h
[11]. A post hoc analysis of patients randomized between
5.5–12h after last time known well from the ESCAPE trial
showed similar rates of favorable outcome as in the DAWN
and DEFUSE-3 trial [15], indicating that collaterals can
be used for triage of stroke patients in the late time win-
dow. Furthermore, recently published work from Kim et al.
and Almekhlafi et al. indicated that the treatment modify-
ing effect of collaterals is of equal magnitude as perfusion-
based paradigms in late time window patients, while po-
tentially selecting more patients eligible for MT [16, 17].
Using only the DAWN and DEFUSE 3 criteria based on
perfusion for the selection of late window patients might
lead to the exclusion of patients who would benefit from
MT. In a recently published sample 38% of the DAWN-in-
eligible and 41% of the DEFUSE 3-ineligible patients had
a good functional outcome at 90 days (mRS ≤2) [18]. As
of now, optimal eligibility criteria for MT in the late win-
dow are not available; however, ongoing trials such as the
TENSION (NCT03094715) trial might provide a better ba-
sis for evidence-based decisions with respect to MT in late-
window stroke patients.
Another important aspect of our work was the com-
parison of the ischemic core and penumbra estimates of
the different software packages. We showed that there are
substantial differences in the estimates of the four software
packages. Core volume estimates of OLEA and RAPID
were similar, while we found relevant differences in the
core volume estimation between VEOcore and RAPID
(mean difference +13.4ml) and syngo.via and RAPID
(mean difference +30ml). We also found relevant differ-
ences between RAPID and OLEA regarding the estimation
of the penumbra volume (mean difference +41.9ml). As
for the mean differences between the core volume esti-
mates of syngo.via/OLEA and RAPID our results are in
line with smaller, previously published studies [19–21].
The VEOcore and penumbra volumes were not system-
atically evaluated so far. Consequently, our results pose
a substantial limitation to the utilization of the DAWN and
DEFUSE-3 criteria on core volumes derived from VEOcore
and syngo.via, as they might substantially overestimate the
ischemic core volume and lead to the inappropriate dis-
qualification of patients who are eligible for MT using
the DAWN and DEFUSE-3 criteria. On the other hand,
the possible overestimation of the penumbra volume in
OLEA would not lead to the disqualification of patients.
In our study, the evaluation of core volumes by VEOcore
and syngo.via was not associated with functional outcome
or disability at 90 days. This indicates that the DAWN
and DEFUSE imaging criteria based on RAPID cannot be
applied to the alternative software packages.
While variability and interpretation of perfusion scans
have benefited from automation, important technical chal-
lenges remain such as motion sensitivity, extra radiation and
time delays with acquisition [16]. In our sample 5–7% (de-
pending on the software) of the perfusion scans could not
be processed, while we were able to evaluate all CTAs for
collateral scoring. Another potential shortcoming of a per-
fusion-based paradigm is that the emerging one-stop man-
agement for stroke treatment (utilizing a flat-detector CT
in the angiography suite) has not been evaluated in large
patient cohorts with perfusion-based triage paradigms so
far [22], while collateral scoring functions relatively well
[23]. This deprives late time-window acute stroke patients
of a potential time-saving effect of up to 40min due to
a reduction of in-hospital time delays [24, 25].
The predictive power for disability at 90 days of all ex-
amined paradigms was only modest with ROC values rang-
ing between 0.62 and 0.70. This might be due to the fact
that all of these paradigms do not consider the location of
the ischemic lesion. As was pointed out by Ernst et al. in
a post hoc analysis of the MR CLEAN dataset, the associ-
ation between the infarct core volume and the outcome can
be substantially strengthened by accounting for the mRS
relevance of affected brain areas [26, 27].
One major strength of our study is that we used robust
long-term outcome data, whereas other studies used the fi-
nal infarct volume as a surrogate parameter for outcome
[20, 21]; however, as was recently shown by Boers et al.
in a pooled analysis from 7 randomized controlled trials,
reduced final infarct volume only explained 12% of the
treatment benefit in these trials [28], which was supported
by a secondary analysis of the MR CLEAN data [29]. Since
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it was further shown that the association between final in-
farct volume and functional outcome is only moderate, it
is questionable if this approach is suitable for evaluating
the prognostic power of these software packages [30]. This
notion is supported by our results as VEOcore was an in-
dependent predictor of the posttreatment ASPECTS but not
of the functional outcome. Other strengths of our study in-
clude the high number of patients and the recruitment of
patients from multiple high-volume stroke centers, which
allows generalization of the results over different CT scan-
ner systems.
Certain limitations of the present report need to be
acknowledged. First, this was a retrospective analysis of
prospectively collected data from different registries and
thus our study is prone to selection bias. Second, the CBV-
ASPECTS and collateral score were evaluated by only
one experienced rater, limiting the extent to which our
results can be generalized. Third, we included only patients
with anterior circulation infarctions and were unable to
evaluate the agreement or predictive value of the different
neuroimaging software for the posterior circulation.
Summary
Collateral scoring, CBV-ASPECTS and RAPID were inde-
pendently associated with functional outcome at 90 days.
Core and Penumbra estimates using automated software
packages vary significantly and should therefore be used
with caution.
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